Zhen Wang

Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: Interim results from the phase 2 KEYNOTE-100 study.

D. Provencher, J. Ledermann, M. Birrer, 2018 .

PD-L1 expression and survival in patients with non-small cell lung cancer (NSCLC) in Korea.

Y. Shim, M. Dolled-Filhart, K. Emancipator, 2014 .

Association between certain non–small cell lung cancer driver mutations and predictive markers for chemotherapy or programmed death‐ligand 1 inhibition

W. Liang, Jianxing He, P. He, 2019, Cancer science.

Meta-analysis of FOLFIRINOX regimen as the first-line chemotherapy for locally advanced pancreatic cancer and borderline resectable pancreatic cancer

Xifeng Xu, Changku Jia, Ke Ge, 2018, Clinical and Experimental Medicine.

Prognostic Significance of PD‐L1 in Patients with Non–Small Cell Lung Cancer: A Large Cohort Study of Surgically Resected Cases

Y. Shim, M. Dolled-Filhart, K. Emancipator, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A two centers study of postoperative adjuvant chemotherapy with S-1 versus SOX/XELOX regimens for gastric cancer after D2 resection: a cohort study

Yidan Lu, Song Zheng, Zhen Wang, 2019, Cancer Chemotherapy and Pharmacology.

Neoadjuvant PD-1 Inhibitor Plus Apatinib and Chemotherapy Versus Apatinib Plus Chemotherapy in Treating Patients With Locally Advanced Gastric Cancer: A Prospective, Cohort Study

Fujing Wang, Yue Zhao, Zhen Wang, 2023, Journal of gastric cancer.

PD-L1 Expression and Survival among Patients with Advanced Non–Small Cell Lung Cancer Treated with Chemotherapy

M. Dolled-Filhart, K. Emancipator, Wei Zhou, 2016, Translational oncology.

AI4 CAN WE DECREASE THE SCREENING BURDEN IN SYSTEMATIC REVIEWS? PERFORMANCE OF TWO NATURAL LANGUAGE PROCESSORS TO EXCLUDE RECORDS

Zhen Wang, J. Tetzlaff, M. H. Murad, 2020 .

Pembrolizumab (MK-3475) versus paclitaxel as second-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Phase 3 KEYNOTE-061 study.

Linda Z Sun, Y. Bang, C. Fuchs, 2016 .

Second‐line treatment in patients with pancreatic ductal adenocarcinoma: A meta‐analysis

I. Makhoul, M. Borad, T. Bekaii-Saab, 2017, Cancer.

A phase II study of anlotinib in treating patients with relapsed or metastatic primary malignant bone tumor.

Yang Yao, X. Niu, C. Tu, 2020 .